List of Mektovi drug patents

Mektovi is owned by Array Biopharma Inc.

Mektovi contains Binimetinib.

Mektovi has a total of 11 drug patents out of which 0 drug patents have expired.

Mektovi was authorised for market use on 27 June, 2018.

Mektovi is available in tablet;oral dosage forms.

Mektovi can be used as indicated in combination with encorafenib for the treatment of melanoma with a braf mutation, indicated in combination with encorafenib for the treatment of melanoma, method of treating melanoma, treatment of melanoma with a braf mutation, indicated in combination with encorafenib for the treatment of melanoma mediated by a b-raf protein kinase.

Drug patent challenges can be filed against Mektovi from June, 2022.

The generics of Mektovi are possible to be released after 18 October, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7777050 ARRAY BIOPHARMA INC N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2023

(a month from now)

US8178693 ARRAY BIOPHARMA INC N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2023

(a month from now)

US9562016 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor
Oct, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8513293 ARRAY BIOPHARMA INC Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal
Mar, 2023

(a month from now)

US8193229 ARRAY BIOPHARMA INC Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2023

(a month from now)

US9593100 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US10005761 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US9850229 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US9314464 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Jul, 2031

(8 years from now)

US9598376 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor
Oct, 2033

(10 years from now)

US9980944 ARRAY BIOPHARMA INC Preparation of and formulation comprising a MEK inhibitor
Oct, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 27, 2023
Orphan Drug Exclusivity (ODE) Jun 27, 2025

Drugs and Companies using BINIMETINIB ingredient

NCE-1 date: June, 2022

Market Authorisation Date: 27 June, 2018

Treatment: Indicated in combination with encorafenib for the treatment of melanoma; Method of treating melanoma; Indicated in combination with encorafenib for the treatment of melanoma with a braf mutation; Indicated in combination with encorafenib for the treatment of melanoma mediated by a b-raf protein kinase; Treatment of melanoma with a braf mutation

Dosage: TABLET;ORAL

How can I launch a generic of MEKTOVI before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in